General
Preferred name
FLUDARABINE
Synonyms
NSC 118218 ()
F-ara-A ()
Fludarabinum ()
Fludarabine (NSC 118218) ()
FaraA, Fludarabinum, NSC 118218 ()
2-Fluoro-Ara-A ()
P&D ID
PD002993
CAS
21679-14-1
Tags
natural product
drug
available
Drug Status
approved
Drug indication
Haematological malignancy
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Fludarabine is a chemotherapy drug used to treat blood cancers.
(GtoPdb)
DESCRIPTION
Purine analog; inhibits DNA synthesis
(Tocriscreen Plus)
DESCRIPTION
Wnt/beta-catenin signaling inhibitor; axin stabilizer
(Tocris Bioactive Compound Library)
DESCRIPTION
Purine analog; inhibits DNA synthesis
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
13
Organisms
0
Compound Sets
24
Axon Medchem Screening Library
Cayman Chemical Bioactives
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
39
Molecular Weight
285.09
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
4
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
-1.84
TPSA
139.54
Fraction CSP3
0.5
Chiral centers
4.0
Largest ring
6.0
QED
0.47
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Cell Biology
Pathway
JAK/STAT Signaling
Stem Cells
DNA Damage/DNA Repair
Target
STAT1
DNA synthesis
ADA, DCK, POLA1, RRM1, RRM2
DNA synthesis inhibitor
ADA
Apoptosis related,DNA/RNA Synthesis,Nucleoside Analog/Antimetabolite,STAT
Primary Target
DNA, RNA and Protein Synthesis
MOA
STAT
DNA/RNA Synthesis
Inhibitor
Ribonucleotide Reductase inhibitor
Indication
chronic lymphocytic leukemia (CLL)
Therapeutic Class
Anticancer Agents
Source data
